A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2016
At a glance
- Drugs AK 0529 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Ark Biosciences
- 28 Jun 2016 Status changed from recruiting to discontinued as we switched this study design to another study per IEC's recommendations.
- 19 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 19 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.